Literature DB >> 23954883

Cross-linking of CD81 by HCV-E2 protein inhibits human intrahepatic plasmacytoid dendritic cells response to CpG-ODN.

Zhengkun Tu1, Ping Zhang, Haijun Li, Junqi Niu, Xia Jin, Lishan Su.   

Abstract

Plasmacytoid dendritic cells (pDCs) are reported to be defective in HCV-infected patients, the mechanisms of which remain poorly understood. We isolated liver derived mononuclear cells (LMNCs) and pDCs from normal liver tissues of benign tumor dissections and liver transplant donors. Isolated pDCs and LMNCs were cultured with precoated HCV envelop protein E2 (HCV-E2) or anti-CD81 mAb in the presence of CpG-ODN. Our results show that cross-linking of CD81 by either HCV-E2 or anti-CD81 mAb inhibits IFN-α secretion in CpG-induced pDCs; down-regulates HLA-DR, CD80 and CD86 expression in pDCs; and suppresses CpG-ODN induced proliferation and survival of pDCs. The blockade of CD81 by soluble anti-CD81 antibody restores pDCs response to CpG-ODN. These results suggest that HCV E2 protein interacts with CD81 to inhibit pDC maturation, activation, and IFN-α production, and may thereby contribute to the impaired innate anti-viral immune response in HCV infection.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CpG oligodeoxynucleotides (CpG-ODN); Cross-linking; Hepatitis C virus envelop protein (HCV-E); Plasmacytoid dendritic cells (pDCs); Toll-like receptor 9 (TLR9)

Mesh:

Substances:

Year:  2013        PMID: 23954883      PMCID: PMC3979323          DOI: 10.1016/j.cellimm.2013.07.012

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  33 in total

1.  Binding of the hepatitis C virus envelope protein E2 to CD81 provides a co-stimulatory signal for human T cells.

Authors:  A Wack; E Soldaini; C Tseng; S Nuti; G Klimpel; S Abrignani
Journal:  Eur J Immunol       Date:  2001-01       Impact factor: 5.532

2.  Synergy between TLR3 and IL-18 promotes IFN-γ dependent TRAIL expression in human liver NK cells.

Authors:  Zhengkun Tu; Heli K Hamalainen-Laanaya; Ian Nicholas Crispe; Mark S Orloff
Journal:  Cell Immunol       Date:  2011-07-20       Impact factor: 4.868

3.  Human plasmacytoid dendritic cells phagocytose, process, and present exogenous particulate antigen.

Authors:  Jurjen Tel; Annechien J A Lambeck; Luis J Cruz; Paul J Tacken; I Jolanda M de Vries; Carl G Figdor
Journal:  J Immunol       Date:  2010-03-19       Impact factor: 5.422

4.  Hepatitis C virus core protein subverts the antiviral activities of human Kupffer cells.

Authors:  Zhengkun Tu; Robert H Pierce; Jonathan Kurtis; Yoshio Kuroki; I Nicholas Crispe; Mark S Orloff
Journal:  Gastroenterology       Date:  2009-09-19       Impact factor: 22.682

5.  Cell culture-produced hepatitis C virus impairs plasmacytoid dendritic cell function.

Authors:  Masaaki Shiina; Barbara Rehermann
Journal:  Hepatology       Date:  2008-02       Impact factor: 17.425

6.  TLR9 signals after translocating from the ER to CpG DNA in the lysosome.

Authors:  Eicke Latz; Annett Schoenemeyer; Alberto Visintin; Katherine A Fitzgerald; Brian G Monks; Cathrine F Knetter; Egil Lien; Nadra J Nilsen; Terje Espevik; Douglas T Golenbock
Journal:  Nat Immunol       Date:  2004-01-11       Impact factor: 25.606

7.  CD81/CD9 tetraspanins aid plasmacytoid dendritic cells in recognition of hepatitis C virus-infected cells and induction of interferon-alpha.

Authors:  Shuye Zhang; Karen Kodys; Gregory J Babcock; Gyongyi Szabo
Journal:  Hepatology       Date:  2013-01-18       Impact factor: 17.425

8.  Targeting DCIR on human plasmacytoid dendritic cells results in antigen presentation and inhibits IFN-alpha production.

Authors:  Friederike Meyer-Wentrup; Daniel Benitez-Ribas; Paul J Tacken; Cornelis J A Punt; Carl G Figdor; I Jolanda M de Vries; Gosse J Adema
Journal:  Blood       Date:  2008-02-07       Impact factor: 22.113

9.  Impaired plasmacytoid dendritic cell maturation and differential chemotaxis in chronic hepatitis C virus: associations with antiviral treatment outcomes.

Authors:  J A Mengshol; L Golden-Mason; N Castelblanco; K A Im; S M Dillon; C C Wilson; H R Rosen
Journal:  Gut       Date:  2009-02-04       Impact factor: 23.059

10.  Hepatitis C virus is a weak inducer of interferon alpha in plasmacytoid dendritic cells in comparison with influenza and human herpesvirus type-1.

Authors:  Françoise Gondois-Rey; Clélia Dental; Philippe Halfon; Thomas F Baumert; Daniel Olive; Ivan Hirsch
Journal:  PLoS One       Date:  2009-02-02       Impact factor: 3.240

View more
  5 in total

Review 1.  Current progress in host innate and adaptive immunity against hepatitis C virus infection.

Authors:  Jijing Shi; Yuanyuan Li; Wenxian Chang; Xuexiu Zhang; Fu-Sheng Wang
Journal:  Hepatol Int       Date:  2017-06-22       Impact factor: 6.047

Review 2.  An insight into the diagnosis and pathogenesis of hepatitis C virus infection.

Authors:  Mohammad Irshad; Dhananjay Singh Mankotia; Khushboo Irshad
Journal:  World J Gastroenterol       Date:  2013-11-28       Impact factor: 5.742

3.  Conserved Motifs within Hepatitis C Virus Envelope (E2) RNA and Protein Independently Inhibit T Cell Activation.

Authors:  Nirjal Bhattarai; James H McLinden; Jinhua Xiang; Thomas M Kaufman; Jack T Stapleton
Journal:  PLoS Pathog       Date:  2015-09-30       Impact factor: 6.823

Review 4.  CD81 and hepatitis C virus (HCV) infection.

Authors:  Lucie Fénéant; Shoshana Levy; Laurence Cocquerel
Journal:  Viruses       Date:  2014-02-06       Impact factor: 5.048

Review 5.  Mononuclear phagocyte system in hepatitis C virus infection.

Authors:  Yu Yang; Zheng-Kun Tu; Xing-Kai Liu; Ping Zhang
Journal:  World J Gastroenterol       Date:  2018-11-28       Impact factor: 5.742

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.